Drug-Induced Intestinal Obstruction Signals from 18.5M FAERS Reports

A collection of disproportionality analysis results for 50 suspect drugs linked to intestinal obstruction, derived from 18,532,100 deduplicated FAERS reports spanning Q1 2004 to Q4 2024. It includes reporting odds ratio (ROR) and Bayesian information component (IC) signal magnitudes, time-to-onset analyses, and cross-validation results from the JADER database.

Use Cases

• Analyze the relationship between ROR and IC signal magnitudes across the 50 suspect drugs to identify high-signal therapies.
• Investigate time-to-onset heterogeneity using median and IQR values at the report-drug pair level to characterize delayed-onset events.
• Benchmark signal concordance for the 20 overlapping drugs between FAERS and JADER to assess transportability of pharmacovigilance findings.
• Compare disproportionality signals against product information using the Yes/No/Unclear framework to evaluate label alignment.

Strengths

• Analysis is based on a large source of 18,532,100 unique FAERS reports.
• Includes cross-database validation in JADER for 20 overlapping drugs.
• Provides multiple analytical metrics including ROR, IC, and time-to-onset with median and IQR.

Limitations

• The dataset is a processed analysis output; the underlying raw report-level data is not included.
• Sample size for specific drugs is not provided, limiting granular assessment.
• Findings are described as hypothesis-generating, requiring confirmation in longitudinal studies.

Provenance

Source

FAERS (FDA Adverse Event Reporting System) and JADER (Japanese Adverse Drug Event Report database).

Collection Method

Disproportionality screening and time-to-onset analysis on deduplicated adverse event reports.

Time Range

Q1 2004 to Q4 2024.

Freshness

Data covers reports up to Q4 2024 and was last updated in March 2026.

Geography

Primarily United States (FAERS) with cross-validation in Japan (JADER).